October 22nd 2024
The STOP-CDI intervention presented by Matthew J.Ziegler, MD MSCE revealed using prophylactic enteral vancomycin, significantly reduced hospital-onset C difficile infections among immunocompromised patients.
Top 5 Infectious Disease News Stories Week of September 20-27
September 28th 2024This week, a push for better care standards for C difficile, a survey shows low vaccination rates for respiratory viruses among Americans, Georgia achieves a reduction in chronic hepatitis C infections through collaborative efforts, and more.
Read More
Investigational C Diff Therapy Shows Favorable Microbiome Characteristics, Phase 3 Trial Planned
Published: September 27th 2024 | Updated: September 27th 2024The latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.
Read More
Understanding the Symbiotic Relationship of Biofilms and Vancomycin
September 23rd 2024A new study looked at Bacteroides thetaiotaomicron and C difficile infection (CDI) and their formation of symbiotic biofilms in the antibiotic's environment, and underscore the complexity of CDI prevention and the importance of considering gut microbiomes in treatment strategies.
Read More
Top 5 Infectious Disease News Stories Week of September 13-September 20
September 21st 2024Adults with type 2 diabetes taking metformin have a 13% to 21% lower risk of developing Long COVID or dying from COVID-19, recent analyses question the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new variants, and more this week from Contagion.
Read More
Managing C. difficile Infections in the Clinic
Focusing on the treatment of patients with C. difficile infections, Carl V. Crawford, MD, provides clinical insights on medication tapering practices and therapies being utilized by clinicians.
Watch
Factors Contributing to C. difficile Infection Recurrence
Matthew D. Sims, MD, PhD, FACP, FIDSA, discuss how antibiotics do not completely eliminate C. difficile infections, the drivers of recurrence, and new treatments that are addressing eubiosis and C. difficile spores.
Watch
Assessing the Relationship Between C-diff Risk and Antibiotic Exposure
September 12th 2024C diff remains a major healthcare burden globally, with over 225,000 hospitalizations in the US alone. Over half of these cases had recent antibiotic exposure, underlining the significant relationship between antibiotic use and the risk of the healthcare-associated infection.
Read More
The Significance of Antimicrobial Stewardship in Dentistry
September 9th 2024Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.
Read More
Treatment Guidelines for C. difficile Infection
Experts on C. difficile infections give an overview of the ACG and IDSA/SHEA treatment guidelines for initial infection, first recurrence, and subsequent recurrences.
Watch
Diagnostic Tests for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, provides clinical insights on diagnostic testing practices for C. difficile infections, highlighting the EIA, GDH, and PCR assays.
Watch
Patients at Risk for Recurrent C. difficile Infections and the Role of Environmental Factors
Sahil Khanna, MBBS, MS, outlines patients at risk for recurrent C. difficile infections, and Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA, focuses on environmental considerations that can help prevent transmission.
Watch
Risk Factors for C. difficile Infections
Carl V. Crawford, MD, outlines the risk factors for C. difficile infections, focusing on factors that affect the body’s microbiome or immune system, including antibiotics, age, comorbid conditions, exposures, and prior C. difficile infections.
Watch
Top 5 Infectious Disease News Stories Week of August 23-August 30
August 31st 2024This week, MP Biomedicals launched rapid diagnostic tests for gastrointestinal pathogens, Invivyd's monoclonal antibody pemivibart shows an 84% reduction in symptomatic COVID-19 risk, Nestlé is acquiring global rights to the Vowst therapy for CDI, and more.
Read More
Recurrence of C. Difficile Infections
Teena Chopra, MD, MPH, FACP, FIDSA, FSHEA, and Matthew D. Sims, MD, PhD, FACP, FIDSA, provide clinical insights on the rate of recurrence of C. difficile infections and the impact on patients.
Watch
Epidemiology of C. difficile Infections in the US
A panel of experts provide an overview of the epidemiology of Clostridioides difficile infections, highlighting diagnostic practices and the role of antimicrobial stewardship.
Watch
Updated Details on Vedanta's Phase 3 VE303 Trial for Recurrent C difficile
August 14th 2024Jeffery Silber MD, highlights VE303's consistent formulation as an advantage over traditional fecal transplants and discusses how the trial's patient-centric approach aims to improve outcomes and reduce healthcare-associated infections.
Read More
Top 5 Infectious Disease News Stories: Week of August 2-August 9
August 10th 2024Enhanced diagnostic and surveillance measures for hypervirulent pathogens, new CDC safety data on RSV vaccines showing rare risks, updated IDSA guidance for managing antimicrobial-resistant infections, and more this week from Contagion.
Read More